Science 37, Inc
12121 Bluff Creek Drive
About Science 37, Inc
Science 37 is a Los Angeles-based technology-enabled clinical research company. They created a new clinical trial operating model – the metasite™ – that unlocks access so researchers can find the right patients, and patients can find the right trials. Their Network Orientated Research Assistant, NORA®, is the cloud-based patient-centric mobile research platform that connects everyone – safely and securely. Science 37 offers end-to-end clinical trial services without geographic limitations, making clinical research faster to accelerate biomedical discovery. Ultimately, Science 37 enables better, faster people-powered science and brings clinical trials to scale.
Founder and CEO: Noah Craft
Founder and CMO: Belinda Tan
COO: Jay Trepanier
CTO: Kelly Chu
Please click here for Science 37 job opportunities .
FOLLOW SCIENCE 37:
Tweets by Science 37
40 articles with Science 37, Inc
Science 37® and Foundation Medicine Partner to Enable Interventional Home-Based Clinical Trials in Oncology
Science 37 and Foundation Medicine today announced a collaboration to enable decentralized clinical research in oncology that will optimize recruitment and enrollment, improve patient retention, and expand access to precision cancer care.
Science 37 ® Appoints Christine Pellizzari as Chief Legal Officer
New Science 37® Report: Nearly 100% of Biopharma Executives Expect Clinical Trial Decentralization to Increase Yet Lack Internal Capabilities to Operationalize
New Science 37 ® Report: Nearly 100% of Biopharma Executives Expect Clinical Trial Decentralization to Increase Yet Lack Internal Capabilities to Operationalize
Join Science 37 for a Panel of Health Industry Leaders Exploring “Decentralized Clinical Trials and the Empowered Patient Trial Experience” at Reuters Webinar
Science 37 CEO David Coman alongside executives from Bayer, Sanofi, Merck and Pluto Health will discuss how to build an operating system to ensure patient preferences drive a decentralized clinical trial (DCT) approach during an upcoming Reuters Webinar. WHEN: Thursday, June 24, 2021 at 10:00 am ET.
5/12/2021Catch up on the investment news quickly with BioSpace's brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week.
Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future
Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research
Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds.
Science 37® and Xperiome™ Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers
Using Science 37's decentralized clinical trial model, the partnership offers Xperiome's research-ready, rare disease patients more study opportunities with less burden.
Science 37, the industry leader in decentralized clinical trials, announced a strategic partnership with Medgate, a leading international digital health and telemedicine company and operator of Europe's largest telemedicine center run by physicians.
Science 37® Launches 'Science 37 Certified'--a Partnership Program Enabling CROs to Effectively Execute Decentralized Clinical Trials
Science 37's flexible Science 37 Certified program provides contract research organizations (CROs) with direct access to its Operating System to enable decentralized trial solutions.
Science 37® and Signant Health Partner to Expand Access to CNS Research with Decentralized Clinical Trials
Collaboration enables patients to participate in clinical trials from their homes--broadening patient access and enrollment while strengthening the service offerings across a variety of CNS indications.
Science 37® Launches Integrated Electronic Health Records into Its Industry-Leading Decentralized Clinical Trial Technology Platform
Patients using Science 37's technology platform can now connect their health record directly, in real time--eliminating paper documentation and streamlining information sharing [10-September-2020] LOS ANGELES , Sept.10, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today launched an electronic health record (EHR) integration feat
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Technology partnership enables trial sponsors to improve imaging, respiratory, and cardiac safety data quality while reducing patient burden and risk.
In a significantly oversubscribed offering, Science 37 attracted capital to support its rapid growth, expand its technology platform and accelerate global expansion. [20-August-2020] LOS ANGELES , Aug. 20, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round. Exis
Science 37, the industry leader in decentralized clinical trials, today announced a series of global investments, including an expanded European, Latin American and Asian nurse and investigator network
Science 37, the industry leader in virtual clinical trials, announced today that Mike Zaranek has joined the company as its chief financial officer (CFO). He will oversee all aspects of finance, accounting, and
The partnership combines artificial intelligence with comprehensive virtual trial services to bring novel insights to research
The partnership addresses key concerns for clinical trial sponsors as they transition to virtual trials in light of the COVID-19 pandemic [21-April-2020] LOS ANGELES and COLUMBIA, Md. , April 21, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, and Advarra, a leading institutional review board (IRB), have partnered to expedite app
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.